Dilpacimab

• Description :

  Dilpacimab (ABT165) is a potent dual-variable domain immunoglobulin, targets both delta-like ligand 4 (DLL4) and VEGF pathways.. Dilpacimab can be used in research of cancer[1].

• Product Name Alternative :

  ABT165; PR1283233

• UNSPSC :

  12352203

• Target :

  VEGFR

• Type :

  Inhibitory Antibodies

• Related Pathways :

  Protein Tyrosine Kinase/RTK

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/dilpacimab.html

• Purity :

  96.88

• Solubility :

  10 mM in DMSO

• Smiles :

  [Dilpacimab]

• Molecular Weight :

  (199.12 kDa)

• References & Citations :

  [1]Gordon MS, et, al. Phase I Open-Label Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Dilpacimab in Patients with Advanced Solid Tumors. Mol Cancer Ther. 2021 Oct;20 (10) :1988-1995.

• Shipping Conditions :

  Dry Ice

• Storage Conditions :

  Store at -80°C for 2 years

• Scientific Category :

  Inhibitory Antibodies

• Clinical Information :

  Phase 2

• CAS Number :

  [1791420-09-1]